Pharmacogenomics: an opportunity for personalised psychotropic prescribing in adults with intellectual disabilities
Bhathika Perera1, Charles Steward2, Ken Courtenay1
1Barnet, Enfield and Haringey Mental Health NHS Trust, London, UK.
Abstract:
There is growing evidence for the use of pharmacogenomics in psychotropic prescribing. People with intellectual disabilities are disproportionately prescribed psychotropics and are at risk of polypharmacy. There is an urgent need for safeguards to prevent psychotropic overprescribing but it is equally crucial that this population is not left behind in such exciting initiatives. Understanding how genetic variations affect medications is a step towards personalised medicine. This may improve personalised prescribing for people with intellectual disabilities, especially given the high rate of psychiatric and behavioural problems in this population. Our editorial explores opportunities and challenges that pharmacogenomics offers for the challenges of polypharmacy and overprescribing of psychotropics in people with intellectual disabilities.
More Related Videos
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
Related Concept Videos
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Factors Affecting Drug Response: Overview
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Psychosis: Goals of Pharmacotherapy
Analysis of Population Pharmacokinetic Data
Drug Therapy
Antianxiety Medications
